SynthesisPLoS neglected tropical diseases2021
Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy.
Synthesis in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Pooled it
- Evaluating the efficacy of the praziquantel dose pole for schistosomiasis treatment: A multi-country systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Efficacy of single dose praziquantel against Schistosoma mansoni in East Africa: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Evaluating the efficacy of different praziquantel treatment regimens using egg and circulating anodic antigen (CAA) detection methods in a Schistosoma mansoni endemic area in northeastern Brazil.International journal for parasitology. Drugs and drug resistance · 2025Trial
- Limited efficacy of repeated praziquantel treatment in Schistosoma mansoni infections as revealed by highly accurate diagnostics, PCR and UCP-LF CAA (RePST trial).PLoS neglected tropical diseases · 2022Trial
- Direct measurement ofbioRxiv : the preprint server for biology · 2026Article
- The big picture : Parasites, People and the Path to Ending Schistosomiasis.EMBO reports · 2026Article
- Individual and spatial heterogeneity of praziquantel efficacy against Schistosoma mansoni within the context of repeated mass drug administration.Parasites & vectors · 2026Article
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Access to praziquantel in Italy: persistent gaps and ongoing responses amid a Europe-wide shortage.Infectious diseases of poverty · 2026Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMInternational journal for parasitology. Drugs and drug resistance · 2026Article
- Challenges in the diagnostic of bilharziasis: a case report.International journal of surgery case reports · 2026Article
- Diagnosis of female genital schistosomiasis and pre-emptive treatment with praziquantel: a community-based pilot intervention study in Tiko, Cameroon.Reproductive health · 2026Article
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
- The associations between Schistosoma mansoni infection, pre-treatment symptoms, praziquantel side effects, and treatment efficacy in Ugandan school-aged children.PLoS neglected tropical diseases · 2025Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMbioRxiv : the preprint server for biology · 2025Article
- Adaptive integrated intervention approaches for schistosomiasis elimination in Pemba: A 4-year intervention study and focus on hotspots.PLoS neglected tropical diseases · 2025Article
- Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates.Protein science : a publication of the Protein Society · 2025Article
- Structure-Based Discovery of Phytocompounds from Azadirachta indica as Potential Inhibitors of Thioredoxin Glutathione Reductase in Schistosoma mansoni.Cell biochemistry and biophysics · 2025Article
- How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe antihelminthic drug praziquantel has been used as the drug of choice for treating schistosome infection for more than 40 years. Although some epidemiological studies have reported low praziquantel efficacy in cure rate (CR) and/or egg reduction rate (ERR), there is no consistent robust evidence of the development of schistosome resistance to praziquantel (PZQ). There is need to determine factors that lead to variable treatment CR and/or ERR. Therefore, we conducted a systematic review and meta-analysis to review CR and ERR as well as identify their predictors. METHODOLOGY/PRINCIPAL
findingsIn this systematic review and meta-analysis, a literature review was conducted using Biosis Citation Index, Data Citation Index, MEDLINE, and Web of Science Core Collection all of which were provided through Web of Science. Alongside these, EMBASE, and CAB abstracts were searched to identify relevant articles. Random effect meta-regression models were used to identify the factors that influence CR and/or ERR by considering differences in host characteristics and drug dose. In total, 12,127 potential articles were screened and 146 eligible articles (published from 1979 to 2020) were identified and included for the meta-analysis. We found that there has been no significant reduction in CR or ERR over the study period. The results showed more variability in CR, compared with ERR which was more consistent and remained high. The results showed a positive effect of "PZQ treatment dose" with the current recommended dose of 40 mg/kg body weight achieving 57% to 88% CR depending on schistosome species, age of participants, and number of parasitological samples used for diagnosis, and ERR of 95%. CONCLUSIONS/SIGNIFICANCE: Based on a review of over 40 years of research there is no evidence to support concerns about schistosomes developing resistance to PZQ. These results indicate that PZQ remains effective in treating schistosomiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.